JP2019509014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509014A5 JP2019509014A5 JP2018526708A JP2018526708A JP2019509014A5 JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5 JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- binding
- human
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258701P | 2015-11-23 | 2015-11-23 | |
| US62/258,701 | 2015-11-23 | ||
| US201562263760P | 2015-12-07 | 2015-12-07 | |
| US62/263,760 | 2015-12-07 | ||
| US201562267343P | 2015-12-15 | 2015-12-15 | |
| US62/267,343 | 2015-12-15 | ||
| US201662320738P | 2016-04-11 | 2016-04-11 | |
| US62/320,738 | 2016-04-11 | ||
| US201662404779P | 2016-10-06 | 2016-10-06 | |
| US62/404,779 | 2016-10-06 | ||
| PCT/EP2016/078395 WO2017089334A1 (en) | 2015-11-23 | 2016-11-22 | Cd39 vascular isoform targeting agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509014A JP2019509014A (ja) | 2019-04-04 |
| JP2019509014A5 true JP2019509014A5 (enExample) | 2019-12-12 |
Family
ID=57391960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526708A Pending JP2019509014A (ja) | 2015-11-23 | 2016-11-22 | Ｃｄ３９血管アイソフォームターゲティング剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190153113A1 (enExample) |
| EP (1) | EP3380519A1 (enExample) |
| JP (1) | JP2019509014A (enExample) |
| AU (1) | AU2016359790A1 (enExample) |
| CA (1) | CA3005986A1 (enExample) |
| WO (1) | WO2017089334A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100303828A1 (en) | 2008-01-31 | 2010-12-02 | INSERM Institut National de la Sante et de la Recherche Medicale) | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| WO2018209324A2 (en) * | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| BR112020002012A8 (pt) * | 2017-07-31 | 2022-06-28 | Tizona Therapeutics | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 |
| WO2019068907A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| JP7383609B2 (ja) * | 2017-11-15 | 2023-11-20 | イナート・ファルマ・ソシエテ・アノニム | Ａｔｐ放出の効果の強力化 |
| KR20200108286A (ko) * | 2018-01-10 | 2020-09-17 | 바이오인벤트 인터내셔날 에이비 | 신규한 항체 조합 및 용도 |
| US12060425B2 (en) | 2018-05-03 | 2024-08-13 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| JP2021527138A (ja) * | 2018-06-14 | 2021-10-11 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | エクトヌクレオチダーゼの阻害及び抗体媒介性標的膜動輸送を通じてｔ細胞疲弊を予防又は解除するための組成物及び方法 |
| AU2019289646B2 (en) | 2018-06-18 | 2025-10-23 | Innate Pharma | Compositions and methods for treating cancer |
| CN113727999A (zh) | 2019-01-11 | 2021-11-30 | 奥默罗斯公司 | 用于治疗癌症的方法和组合物 |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
| SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
| JP7765379B2 (ja) | 2019-08-12 | 2025-11-06 | ピュリノミア バイオテック， インコーポレイテッド | Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物 |
| EP3820907A4 (en) * | 2019-08-27 | 2022-05-04 | Elpiscience (Suzhou) Biopharma, Ltd. | NOVEL ANTI-CD39 ANTIBODIES |
| TW202124444A (zh) | 2019-09-16 | 2021-07-01 | 美商表面腫瘤學公司 | 抗ｃｄ３９抗體組合物及方法 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| WO2021088838A1 (zh) * | 2019-11-05 | 2021-05-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| WO2022256483A1 (en) * | 2021-06-03 | 2022-12-08 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
| EP4486785A1 (en) | 2022-03-03 | 2025-01-08 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
| WO2023212483A1 (en) | 2022-04-29 | 2023-11-02 | Purinomia Biotech, Inc. | Methods and compositions for treating eosinophil driven diseases and disorders |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100303828A1 (en) * | 2008-01-31 | 2010-12-02 | INSERM Institut National de la Sante et de la Recherche Medicale) | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity |
| WO2012085132A1 (en) * | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| PL2718322T3 (pl) * | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
-
2016
- 2016-11-22 JP JP2018526708A patent/JP2019509014A/ja active Pending
- 2016-11-22 WO PCT/EP2016/078395 patent/WO2017089334A1/en not_active Ceased
- 2016-11-22 US US15/778,202 patent/US20190153113A1/en not_active Abandoned
- 2016-11-22 AU AU2016359790A patent/AU2016359790A1/en not_active Abandoned
- 2016-11-22 EP EP16800926.4A patent/EP3380519A1/en not_active Withdrawn
- 2016-11-22 CA CA3005986A patent/CA3005986A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3038421T3 (en) | Humanized or chimeric cd3 antibodies | |
| US12227569B2 (en) | Humanized antibodies with increased stability | |
| CN109715663B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| CN101952454B (zh) | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2013545455A5 (enExample) | ||
| JP2014520788A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| US11299551B2 (en) | Composite binding molecules targeting immunosuppressive B cells | |
| CN112334486B (zh) | 用于治疗癌症的组合物和方法 | |
| JP2023076596A5 (enExample) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| TW202509068A (zh) | 結合ox40l之抗體及使用方法 | |
| CA3146977A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| JP2023511652A (ja) | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 | |
| CN110709417A (zh) | 具有突变人IgG4的多肽 | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| EP4417626A1 (en) | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof | |
| US20240352156A1 (en) | Antibodies targeting immunosuppressive b cells | |
| AU2017365367A1 (en) | Monoclonal antibody directed to FGFR1 | |
| CN118139639A (zh) | 治疗与免疫抑制b细胞相关联的癌症的方法 | |
| KR20210116429A (ko) | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 | |
| CN121443643A (zh) | 基于沉默抗体的抗met构建体用于治疗肿瘤和转移 | |
| JP2019517813A5 (enExample) |